

Japan's Saisei Ventures launches bridge-to-biotech venture creation initiative

10 February 2026 | News

For academic scientists and founders who are beginning the company formation process and seeking structured guidance and support



Saisei Ventures, a pioneering investment firm focused on advancing Japanese biotechnology and therapeutic innovations globally, announced the launch of Bridge-to-Biotech, a new initiative designed to support Japanese founders and entrepreneurs as they translate groundbreaking scientific discoveries into venture-ready biotechnology companies.

Bridge-to-Biotech reflects Saisei's commitment to company creation from the earliest stages of innovation, when clarity of direction and early execution play a meaningful role in shaping long-term outcomes. The programme is designed initially for academic scientists and founders who are beginning the company formation process and seeking structured guidance and support as they shape their scientific and commercial vision.

By initiating working with founders in the discovery stage, Bridge-to-Biotech engages entrepreneurs at a key inflection point, when fundamental decisions about development strategy and operations are being made.

As a venture creation programme, Bridge-to-Biotech supports specific ideas independent of an investment outcome. The program provides hands-on guidance across key early milestones, including the design of proof-of-concept experiments, development of IND-track plans, and early company-building strategy. Founders will meet with experienced biotech and pharma mentors to assist in developing pitch materials, equipping them with everything they will need to effectively communicate their vision to investors and partners.